Travere Therapeutics Plunges 15.18% Amid FDA Review Concerns

On May 16, 2025, Travere Therapeutics experienced a significant drop of 15.18% in pre-market trading, sparking concerns among investors and analysts alike.

Travere Therapeutics' stock price plummeted following the announcement that the FDA has scheduled an advisory meeting to review the supplemental use of its kidney drug. This development has raised questions about the drug's regulatory approval and its potential market impact.

Despite the market's initial reaction, some analysts believe that the long-term prospects for Travere Therapeutics remain positive. The company's innovative approach to kidney disease treatment has garnered attention in the medical community, and its pipeline of drugs continues to show promise.

Investors are closely monitoring the situation, as the outcome of the FDA's advisory meeting could have significant implications for the company's future. The meeting is expected to provide more clarity on the regulatory path forward for the kidney drug, which could either bolster or dampen investor confidence.